Hybrid Cell Lines

Hybrid Cell Lines are created by fusing two different cell types, combining their genetic and functional properties. This category covers hybrid cell lines and hybridoma cell lines.

The most common application is hybridoma technology for monoclonal antibody production, for which Georges Köhler and César Milstein won the Nobel Prize in 1984. Hybridoma cell lines are generated by fusing antibody-producing B cells (typically from immunized mice) with immortal myeloma cells that have lost the ability to produce their own antibodies. B cell hybridoma produces specific monoclonal antibodies against a target antigen; these hybridomas are screened by ELISA and cloned by limiting dilution. T cell hybridoma is used to study T-cell receptor signaling, cytokine production (e.g., IL-2), and antigen presentation; they are created by fusing primary T cells with a T-cell lymphoma line. Dendritic cell hybridoma helps study antigen presentation and T-cell activation; they are created by fusing dendritic cells with a fusion partner. Macrophage hybridoma is used for phagocytosis, cytokine release, and inflammasome studies; they retain macrophage functions such as Fc receptor-mediated phagocytosis.

Somatic cell hybrids are formed by fusing two somatic cells (e.g., human and mouse fibroblasts), often used for gene mapping, dominance studies, and epigenetic reprogramming. Fusion partners are the immortal cell lines used in fusions, typically HAT-sensitive cells that cannot survive in HAT medium (hypoxanthine-aminopterin-thymidine) because they lack the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) or thymidine kinase (TK). Common myeloma fusion partner lines include SP2/0 (mouse myeloma, non-secreting, widely used for hybridoma generation), NS1 (NS-1, mouse myeloma, secretes kappa light chain but can be used), P3X63Ag8 (mouse myeloma, secretes IgG, used in early hybridoma work), and FOX-NY (a myeloma line used for rat hybridomas). SP2/0 is a non-secreting mouse myeloma line that is HAT-sensitive and produces no endogenous immunoglobulin chains, making it ideal for generating monoclonal antibodies. NS1 is also a mouse myeloma; it secretes a kappa light chain but can be fused with B cells to produce hybridomas that secrete only the B-cell-derived antibody after appropriate selection. P3X63Ag8 is an older fusion partner that secretes IgG; it is still used for some applications. FOX-NY is a myeloma line used for rat hybridomas, enabling production of rat monoclonal antibodies. These myeloma cell lines provide immortal growth while the B cell contributes antibody genes; the resulting hybrid cells are selected in HAT medium.

Hybrid cells can also be formed between different species (e.g., mouse-human hybrids) for gene mapping and production of human antibodies in mouse cells. Heterokaryons are multinucleated hybrids formed by cell fusion (e.g., using polyethylene glycol or electrofusion) where nuclei remain separate; they are used for studying nuclear-cytoplasmic interactions and reprogramming. Synkaryons result from nuclear fusion where nuclei combine; they are used for somatic cell genetics. Cybrids (cytoplasmic hybrids) retain donor cytoplasm (including mitochondria) but the recipient nucleus; they are used for mitochondrial disease research and studies on cytoplasmic inheritance. Hybrid hybridomas (quadromas) are fusions between two hybridomas, producing bispecific antibodies that bind two different antigens; they are used for cancer immunotherapy (e.g., targeting both tumor cells and T cells).

Researchers use hybridoma cell lines to generate monoclonal antibodies against virtually any antigen. B cell hybridoma technology revolutionized immunology and diagnostics. Somatic cell hybrids are used for human gene mapping; for example, human-mouse hybrids were used to map the location of the HLA genes on chromosome 6. Myeloma fusion partner lines like SP2/0 are essential for stable hybridoma production; they are grown in HAT medium after fusion to select against unfused myeloma cells. T cell hybridoma lines are used for IL-2 release assays to study T-cell activation; they can be used to screen for antigens and superantigens. Hybrid hybridomas produce bispecific antibodies for cancer immunotherapy, such as catumaxomab (anti-EpCAM and anti-CD3). Whether you need dendritic cell hybridoma for antigen presentation studies, macrophage hybridoma for phagocytosis assays, or a B cell hybridoma for custom antibody production, our Hybrid Cell Lines category supports your fusion-based research with validated fusion partners and protocols.